Clinical Trials Directory

Trials / Completed

CompletedNCT01867242

Methods Project 4: Clinical Trial

PROJECT 4: CLINICAL TRIAL METHODS FOR ASSESSING A TOBACCO PRODUCT Part of "MODELS FOR TOBACCO PRODUCT EVALUATION

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
150 (actual)
Sponsor
University of Minnesota · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Cigarette smokers who are eligible will enter a Camel Snus sampling phase. Smokers interested in continuing with the study after the sampling phase will undergo a 2 week baseline assessment phase and will then be randomized to one of the three experimental conditions for 8 weeks. Tobacco use patterns, subjective responses to product, and nicotine and toxicant exposure will be assessed.

Detailed description

Baseline smoking period: Subjects will be required to attend 2 baseline clinic visits where baseline assessments will be captured including a record of their cigarette or other tobacco intake on a daily basis using an interactive voice response system (IVR). Experimental Period: After the baseline assessment, subjects will be randomized to one of five experimental conditions: 1) smoking usual brand cigarette controls, who after 8-weeks will be offered Camel Snus to use as they will for 8 more weeks; 2) complete substitution (i.e., no smoking) and use snus instead ; 3) partial substitution - use of both snus and cigarettes as you like. Snus, but not cigarettes, will be provided to subjects at the clinic visits. Subjects will attend clinic visits over the next 8 weeks where tobacco use patterns and biomarker data will be collected.

Conditions

Interventions

TypeNameDescription
OTHERCigarettesSmoke their usual brand of cigarettes and follow their normal patterns of use.
OTHERSnusWinterchill or Robust flavors

Timeline

Start date
2013-07-01
Primary completion
2017-02-01
Completion
2018-05-01
First posted
2013-06-03
Last updated
2023-05-03
Results posted
2023-04-25

Locations

3 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01867242. Inclusion in this directory is not an endorsement.